These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21537149)

  • 21. Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma.
    Torok JA; Wu Y; Prosnitz LR; Kim GJ; Beaven AW; Diehl LF; Kelsey CR
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):54-9. PubMed ID: 25863754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience.
    Rose A; Grajales-Cruz A; Lim A; Todd A; Bello C; Shah B; Chavez J; Pinilla-Ibartz J; Saeed H; Sandoval-Sus J; Isenalumhe L; Sokol L
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):132-138. PubMed ID: 32950461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.
    Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Wells WA; Winter JN; Horning SJ; Dar AR; Shustik C; Stewart DA; Crump M; Djurfeldt MS; Chen BE; Shepherd LE; ;
    N Engl J Med; 2012 Feb; 366(5):399-408. PubMed ID: 22149921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence.
    Seshachalam A; Karpurmath SV; Rathnam K; Raman SG; Janarthinakani M; Prasad K; Patil C; Anoop P; Reddy N; Anumula SK; Roopa SP; Golamari KR; Danthala M; Gunari P; Malipatil B; Rangarajan B; Udupa KS; Nandennavar M; Niraimathi K; Shewade HD
    J Glob Oncol; 2019 Nov; 5():1-13. PubMed ID: 31834832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial.
    Mounier N; Brice P; Bologna S; Briere J; Gaillard I; Heczko M; Gabarre J; Casasnovas O; Jaubert J; Colin P; Delmer A; Devidas A; Bachy E; Nicolas-Virelizier E; Aoudjhane A; Humbrecht C; Andre M; Carde P;
    Ann Oncol; 2014 Aug; 25(8):1622-8. PubMed ID: 24827123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials.
    Böll B; Görgen H; Fuchs M; Pluetschow A; Eich HT; Bargetzi MJ; Weidmann E; Junghanß C; Greil R; Scherpe A; Schmalz O; Eichenauer DA; von Tresckow B; Rothe A; Diehl V; Engert A; Borchmann P
    J Clin Oncol; 2013 Apr; 31(12):1522-9. PubMed ID: 23509310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ABVD chemotherapy with reduced radiation therapy rates in children, adolescents and young adults with all stages of Hodgkin lymphoma.
    Marr KC; Connors JM; Savage KJ; Goddard KJ; Deyell RJ
    Ann Oncol; 2017 Apr; 28(4):849-854. PubMed ID: 28327925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
    Straus DJ; Długosz-Danecka M; Connors JM; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Munoz J; Lee HJ; Kim WS; Advani R; Ansell SM; Younes A; Gallamini A; Liu R; Little M; Fenton K; Fanale M; Radford J
    Lancet Haematol; 2021 Jun; 8(6):e410-e421. PubMed ID: 34048680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial.
    Chisesi T; Federico M; Levis A; Deliliers GL; Gobbi PG; Santini G; Luminari S; Linfomi MB;
    Ann Oncol; 2002; 13 Suppl 1():102-6. PubMed ID: 12078888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients.
    Colonna P; Jais JP; Desablens B; Harousseau JL; Brière J; Boasson M; Lemevel A; Casassus P; Le Prisé PY; Guilhot F; Ghandour C; Lejeune F; Andrieu JM
    J Clin Oncol; 1996 Jun; 14(6):1928-35. PubMed ID: 8656262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
    Chisesi T; Bellei M; Luminari S; Montanini A; Marcheselli L; Levis A; Gobbi P; Vitolo U; Stelitano C; Pavone V; Merli F; Liberati M; Baldini L; Bordonaro R; Pesce EA; Federico M
    J Clin Oncol; 2011 Nov; 29(32):4227-33. PubMed ID: 21990405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
    Iannitto E; Minardi V; Gobbi PG; Calvaruso G; Tripodo C; Marcheselli L; Luminari S; Merli F; Baldini L; Stelitano C; Callea V; Petrini M; Angrilli F; Quarta G; Vallisa D; Molica S; Liardo E; Polimeno G; Brugiatelli M; Federico M
    Clin Lymphoma Myeloma; 2009 Apr; 9(2):138-44. PubMed ID: 19406724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.
    Advani RH; Hong F; Fisher RI; Bartlett NL; Robinson KS; Gascoyne RD; Wagner H; Stiff PJ; Cheson BD; Stewart DA; Gordon LI; Kahl BS; Friedberg JW; Blum KA; Habermann TM; Tuscano JM; Hoppe RT; Horning SJ
    J Clin Oncol; 2015 Jun; 33(17):1936-42. PubMed ID: 25897153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma.
    Park SI; Shea TC; Olajide O; Reddy NM; Budde LE; Ghosh N; Deal AM; Noe JF; Ansell SM
    Blood Adv; 2020 Jun; 4(11):2548-2555. PubMed ID: 32516414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
    Straus DJ; Długosz-Danecka M; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Connors JM; Radford J; Munoz J; Kim WS; Advani R; Ansell SM; Younes A; Miao H; Liu R; Fenton K; Forero-Torres A; Gallamini A
    Blood; 2020 Mar; 135(10):735-742. PubMed ID: 31945149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.
    Russo F; Corazzelli G; Frigeri F; Capobianco G; Aloj L; Volzone F; De Chiara A; Bonelli A; Gatani T; Marcacci G; Donnarumma D; Becchimanzi C; de Lutio E; Ionna F; De Filippi R; Lastoria S; Pinto A
    Br J Haematol; 2014 Jul; 166(1):118-29. PubMed ID: 24673727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy.
    Gobbi PG; Bassi E; Bergonzi M; Merli F; Coriani C; Iannitto E; Luminari S; Polimeno G; Federico M
    Hematol Oncol; 2012 Dec; 30(4):194-9. PubMed ID: 22271092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hybrid MOPP/ABVD and radiotherapy in advanced Hodgkin's disease.
    Salvagno L; Sorarù M; Sotti G; Aversa S; Chiarion Sileni V; Mazzarotto R; Scarzello G; Bianco A; Pappagallo GL; Fiorentino MV
    Ann Oncol; 1995 Feb; 6(2):173-9. PubMed ID: 7540419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of early clinically staged Hodgkin's disease with a combination of ABVD chemotherapy plus limited field radiotherapy.
    Karmiris TD; Grigoriou E; Tsantekidou M; Spanou E; Mihalakeas H; Baltadakis J; Apostolidis J; Pagoni M; Karakasis D; Bakiri M; Mitsouli C; Harhalakis N; Nikiforakis E
    Leuk Lymphoma; 2003 Sep; 44(9):1523-8. PubMed ID: 14565654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
    Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
    Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.